ABSTRACT
The relationship between sleep traits and survival in breast cancer is uncertain and complex. There are multiple biological, psychological and treatment-related factors that could link sleep and cancer outcomes. Previous studies could be biased due to methodological limitations such as reverse causation and confounding. Here, we used two-sample mendelian randomisation (MR) to investigate the causal relationship between sleep and breast cancer mortality.
Publicly available genetic summary data from females of European ancestry from UK Biobank and 23andme and the Breast Cancer Association Consortium were used to generate instrumental variables for sleep traits (chronotype, insomnia symptoms, sleep duration, napping, daytime-sleepiness, and ease of getting up (N= 446,118-1,409,137)) and breast cancer outcomes (15 years post-diagnosis, stratified by tumour subtype and treatment (N=91,686 and Ndeaths=7,531 over a median follow-up of 8.1 years)). Sensitivity analyses were used to assess the robustness of analyses to MR assumptions.
Initial results found some evidence for a per category increase in daytime-sleepiness reducing overall breast cancer mortality (HR=0.34, 95% CI=0.14, 0.80), and for insomnia symptoms reducing odds of mortality in oestrogen receptor positive breast cancers not receiving chemotherapy (HR=0.18, 95% CI=0.05, 0.68) and in patients receiving aromatase inhibitors (HR=0.23, 95% CI=0.07, 0.78). Importantly, these relationships were not robust following sensitivity analyses meaning we could not demonstrate any causal relationships.
This study did not provide evidence that sleep traits have a causal role in breast cancer mortality. Further work characterising disruption to normal sleep behaviours and its effects on tumour biology, treatment compliance and quality of life are needed.
Competing Interest Statement
DAL has received support from Roche Diagnostics and Medtronic Ltd for research unrelated to that presented here. TR has received grants from Daiichi-Sankyo and Amgen to attend educational workshops. All other authors have no competing interests to declare. The funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The authors alone are responsible for the views expressed in this article.
Funding Statement
BH is funded by an Above & Beyond breast cancer legacy grant from University Hospitals Bristol NHS Foundation Trust (www.aboveandbeyond.org.uk). LF is core-funded by the University of Strathclyde. OM is funded by the Business and Local Government Data Research Centre (BLG DRC) (ES/S007156/1). BH, TR, RMM, DAL and RCR are supported by or affiliated with the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council (MC_UU_00032/01, MC_UU_00032/04, and MC_UU_00032/05) (www.mrc.ukri.org) and the University of Bristol. RMM and DAL are also supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, which is funded by the National Institute for Health Research (NIHR) (www.nihr.ac.uk) and is a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. DAL and RMM are NIHR Senior Investigators (NF-0616-10102, NIHR202411). RMM and RCR are supported by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). TR is supported by an NIHR Development and Skills and Enhancement Award (DSE) (NIHR 302363). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Department of Health and Social Care disclaimer: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the UKB data access committee, and informed consent was obtained from all participants. All participating UKB, 23andMe and BCAC studies were approved by their appropriate ethics or institutional review board and all participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This research was conducted using the UK Biobank Resource under application number 16391. Summary data for the morning-preference, sleep duration, napping, daytime-sleepiness and ease of getting up in the morning GWAS used in this study are available at: https://sleep.hugeamp.org/dinspector.html?dataset=GWAS_UKBB_eu Summary data for the insomnia symptoms GWAS used in this study are available at: https://pubmed.ncbi.nlm.nih.gov/35835914/ Summary data for breast cancer subtype survival GWAS used in this study are available at: https://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/oncoarray-and-combined-summary-result/gwas-summary-results-survival-2021/
